Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03256344
Title Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Amgen
Indications

triple-receptor negative breast cancer

colorectal cancer

Therapies

Atezolizumab + Talimogene laherparepvec

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.